Currently out of the existing stock ratings of Mathew Blackman, 51 are a HOLD (33.33%), 102 are a BUY (66.67%).

Mathew Blackman

Work Performance Price Targets & Ratings Chart

Analyst Mathew Blackman, currently employed at TD COWEN, carries an average stock price target met ratio of 64.67% that have a potential upside of 33.12% achieved within 160 days. Previously, Mathew Blackman worked at STIFEL.

Mathew Blackman’s has documented 297 price targets and ratings displayed on 20 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on PODD, Insulet at 06-Aug-2026.

Wall Street Analyst Mathew Blackman

Analyst best performing recommendations are on CSII (CARDIOVASCULAR SYSTEMS).
The best stock recommendation documented was for CSII (CARDIOVASCULAR SYSTEMS) at 2/3/2022. The price target of $18 was fulfilled within 4 days with a profit of $1.86 (11.52%) receiving and performance score of 28.81.

Average potential price target upside

of $35.35 (16.93%) on PEN (PENUMBRA).
of $17.07 (22.18%) on DXCM (DEXCOM).
of $14.1 (5.97%) on PODD (INSULET).

AHCO Adapthealth Corp ATEC Alphatec Holdings CERS Cerus DXCM DexCom GMED Globus Medical NUVA NuVasive OFIX Orthofix Medical SENS Senseonics Holdings SPNE SeaSpine Holdings Corp CSII Cardiovascular Systems ELGX Endologix INGN Inogen APEN Apollo Endosurgery PODD Insulet TNDM Tandem Diabetes Care WMGI Wright Medical Group N.V CLPT Clearpoint Neuro PEN Penumbra SIBN Si-Bone NARI Inari Medical

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Ben Hendrix (RBC)